Rigel acquires U.S. rights to Blueprint's pralsetinib for $15M plus milestones

RIGEL PHARMACEUTICALS INC

Purchase price $15M: $10M at first commercial sale, $5M one year after closing.
Up to $97.5M in commercial milestones and $5M in regulatory milestones.
Blueprint receives tiered royalties of 10-30% on net sales of pralsetinib products.
Pralsetinib is an approved RET inhibitor for metastatic NSCLC and advanced thyroid cancer.
Rigel expects to recognize product sales starting in Q3 2024 using its commercial infrastructure.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.